Exelixis | EXEL - 市值



金融业
股票价格
USD
资产
USD 2.59B
现金及等价物
USD 226.15M
销售成本
USD 19.95M
流动资产
USD 1.21B
流动负债
USD 370.98M
债务
USD 169.54M
EBIT
USD 251.34M
EBITDA
USD 258.29M
员工
1.15K
EPS每股收益
USD 0.87
股本和储备
USD 1.94B
销售毛利
USD 590.86M
债务利息支出
USD 23.4M
利息收入
USD 16.13M
市值
USD 14.9B
净收入
USD 210.47M
营业费用
USD 359.47M
营业利润
USD 251.34M
普通股股本
USD 253.7M
PE价格收益
13.91
税前利润
USD 267.69M
销售收入
USD 610.8M
销售和管理费用
USD 139.6M
股票
USD 26.61M
贸易债权人
USD 24.15M
应收帐款人
USD 328.95M


市值 更改 日
Acadia Pharmaceuticals USD 3.8B 724M 2026-03
Agios Pharmaceuticals USD 2.01B 423M 2026-03
Akebia Therapeutics USD 427M 297M 2025-12
Amgen USD 189.89B 13.64B 2026-03
AstraZeneca USD 301.25B 13.1B 2026-03
Bayer EUR 38.69B 2.33B 2026-03
BioMarin Pharmaceutical USD 10.86B 553M 2026-03
Bristol-Myers Squibb USD 123.83B 14.02B 2026-03
Cytokinetics USD 8.19B 420M 2026-03
Eisai JPY 1.42T 110.62B 2026-03
Eli Lilly USD 869.02B 146.97B 2026-03
Esperion Therapeutics USD 885M 351M 2025-12
Exelixis USD 10.89B 857M 2026-03
Genmab DKK 20.48B 1.02B 2025-12
Incyte USD 18.73B 660M 2026-03
Ionis Pharmaceuticals USD 12.46B 356M 2026-03
Merck USD 297.1B 35.84B 2026-03
Moderna USD 20.15B 8.53B 2026-03
Nektar Therapeutics USD 11.91B 11.05B 2026-06
Neurocrine Biosciences USD 13.25B 890M 2026-03
Novartis USD 307.76B 15.54B 2026-03
Pfizer USD 153.81B 12.24B 2026-03
Takeda JPY 9.01T 1.37T 2026-03
Ultragenyx Pharmaceutical USD 2.06B 159M 2026-03
Xencor USD 893M 200M 2026-03